PITTSBURGH, Aug. 17 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), a partnership to put the region's life sciences industry on a fast track for growth, today announced that Nurel Therapeutics, Inc., has leased laboratory space in the PLSG Incubator.
Nurel Therapeutics is a specialty biotechnology company developing products to treat and manage pain and peripheral nerve damage, and is expanding into vascular disease. The company's products use a proprietary drug-delivery technology derived from an "inert" herpes simplex virus that provides gene-based medicine in a safe and effective manner.
"Nurel has raised some initial funds to help develop our first product candidate, NPE1, a treatment for chronic pain that has a potential market of $1 billion in the United States," said Frank Tufaro, Ph.D., Nurel's founder, President and Chief Executive Officer. "We are very encouraged by the amount of support we are receiving, particularly from the Pittsburgh Life Sciences Greenhouse."
"The PLSG Incubator will provide Nurel with the working environment it needs to take its initial product into Phase One clinical studies and hopefully a dynamic phase of growth for the company," said Doros Platika, M.D. PLSG Chief Executive Officer. "The PLSG is confident that Nurel Therapeutics and others like it will continue to shape a strong and prosperous life sciences community in the region, improving the quality of medical care, creating good jobs and saving lives."
About the PLSG Incubator
The PLSG Incubator is co-located with the PLSG administrative and support functions, which together occupy 17,000 square feet of space on the fourth floor of Bridgeside Point, better known as the Cellomics Building on Technology Drive in Pittsburgh. Incubator facilities consist of 40 percent lab and 60 percent office space and houses 13 life sciences organizations, which also have convenient access to other services programs offered by the PLSG.
About the PLSG
The Pittsburgh Life Sciences Greenhouse is a public/private partnership, founded by the University of Pittsburgh, Carnegie Mellon University, UPMC Health System, the Commonwealth of Pennsylvania and its regional foundation community. Together with private industry and advanced research and healthcare capabilities of our institutional partners, PLSG invests in and supports the growth of regional life sciences companies in the areas of: bioinformatics; bionanotechnology; diagnostics; medical devices; medical robotics; therapeutics; and tools and services. These companies are focused in the following sectors: drug discovery tools and targets, biomedical devices, tissue engineering and neurological/psychiatric strategy companies.
Pittsburgh Life Sciences Greenhouse (PLSG)